Trial Profile
The effects of tolvaptan on renal handling of water and sodium, vasoactive hormones and circulatory system, during basal conditions and during inhibition of the nitric oxide system in healthy subjects. A dose-response study.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary)
- Indications Hyponatraemia; Kidney disorders
- Focus Pharmacodynamics
- Acronyms DOVA
- 20 Dec 2014 Status changed from active, no longer recruiting to completed as reported by EU Clinical Trials Register record.
- 08 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 26 Jun 2014 New trial record